An immune system is required in any host that evolves slowly relative to the pathogens that attack it. This immune system must somatically generate and regulate new specificities. A history of immunological modelsref :
|
|
|
|
humoral factors | complement![]() surfactant proteins ![]() |
bacterial clearanceref1, ref2, ref3, ref4 | clearance of apoptotic cells![]() |
MBP![]() |
bacterial clearanceref1, ref2, ref3 | clearance of apoptotic cells![]() |
|
LBP![]() ![]() ![]() |
shuttle of PAMPs to TLRsref1, ref2, ref3, ref4 | lipid transfer and mammary-gland involutionref1, ref2 | |
apolipoproteins![]() ![]() |
neutralization of LPS and bacterial clearanceref1, ref2, ref3, ref4, ref5 | lipid transferref1, ref2, ref3, ref4 | |
membrane receptors | Toll | recognition of PAMPsref1, ref2, ref3, ref4 | dorsoventral patterningref |
Toll-like
receptors (TLRs)![]() |
recognition of PAMPsref1, ref2 | recognition of endogenous ligandsref1, ref2, ref3 | |
scavenger receptors![]() |
recognition of PAMPsref1, ref2 | clearance of apoptotic cells![]() |
|
|
|
|
exogenous ligands evoking defence mechanisms | lipoteichoic acid, Gram-negative and -positive bacteriaref1, ref2, ref3, ref4 |
|
|
LPS![]() |
|
|
|
Plasmodium-infected RBCsref |
|
|
|
endogenous ligands | amyloid b-protein![]() ![]() |
|
|
acetylated or oxidized
LDLs (oxLDLs)![]() ![]() |
|
|
|
oxidized
HDL![]() modified RBCsref1, ref2 and phosphatidylserineref |
|
|
|
|
|
|
collectin-family proteins | surfactant protein
A![]() |
lipomannanref,
lipoarabinomannan (LAM)ref
and Pseudomonas
aeruginosa![]() |
apoptotic cells![]() phosphatidylglycerol, phosphatidylserine, cardiolipin, lipoglycans, galactoceramide, sphingophospholipid, glycosphingolipids and dipalmitoyl phosphatidylcholineref1, ref2, ref3 |
surfactant
protein D![]() |
LPS![]() ![]() ![]() ![]() |
apoptotic cells![]() |
|
MBP![]() |
Staphylococcus
aureus![]() ![]() ![]() |
apoptotic cells![]() |
|
lipid-transport proteins (LTPs) | BPI![]() |
LPS![]() |
phosphatidylcholineref |
LBP![]() |
Escherichia coli![]() ![]() |
phosphatidylinositol, phosphatidylcholine and
phosphatidylethanolamineref1, ref2, ref3 |
|
PLTP![]() |
LPS![]() |
phospholipidsref | |
CD14![]() |
LPS![]() ![]() ![]() |
phosphatidylinositol, phosphatidylethanolamineref | |
apolipoproteins![]() |
LPS![]() ![]() ![]() |
cholesterol and triglycerideref and amyloid proteinsref | |
complement | C1q![]() |
liposomeref;
streptococcal lipoteichoic
acid![]() ![]() ![]() ![]() ![]() ![]() ![]() |
cellular and subcellular membranes obtained from the heart, liver and
brain tissue from humans, baboons, cattle, rabbits and ratsref;
substances released on brain contusions, without open injuryref;
mitoplasts derived from human heart mitochondriaref;
cardiolipinref;
aminophospholipidsref;
fragment of activated Hageman factorref;
b-amyloid![]() ![]() |
|
|
|
|
|
|
|
|
|
|
|
---|---|---|---|---|---|---|---|---|---|---|
M
|
34
|
AML
|
4
|
2
|
+
|
(?)
|
Normal
|
24+
|
||
M
|
52
|
APL
|
0.5
|
7
|
+
|
+
|
ND
|
8
|
||
M
|
28
|
APL
|
2
|
NR
|
+
|
+
|
?
|
100+
|
||
M
|
56
|
AML M1
|
2
|
34
|
+
|
+
|
Complex
|
56+
|
||
M
|
73
|
AML M4
|
2
|
?
|
+
|
+ (?)
|
ND
|
3
|
||
F
|
21
|
AML M2
|
?
|
NR
|
+
|
+
|
ND
|
6+
|
||
F
|
53
|
Hypoplastic L
|
8
|
5
|
+
|
+
|
Normal
|
24
|
||
F
|
54
|
AML M2
|
1
|
1
|
|
|
Normal
|
6+
|
||
M
|
51
|
Hypoplastic L
|
1
|
4
|
+
|
+
|
Tetraploid
|
?
|
||
F
|
28
|
APL
|
1
|
2
|
|
+
|
Termination of pregnancy
|
ND
|
6
|
|
M
|
70
|
AML
|
?
|
5
|
+
|
+
|
?
|
6
|
||
M
|
69
|
AML M5a
|
1
|
3
|
|
|
ND
|
15+
|
||
F
|
47
|
AML M5b
|
1
|
NR
|
|
|
+8
|
12+
|
||
F
|
74
|
AML M5
|
1
|
7
|
|
|
Complex
|
25
|
||
F
|
49
|
AML M5a
|
0.5
|
6
|
|
(?)
|
ND
|
10
|
||
M
|
48
|
AML M2
|
13
|
36
|
+
|
+
|
t(8;21), y
|
38
|
||
F
|
41
|
AML M5
|
13
|
14
|
+
|
+
|
Normal
|
17
|
||
M
|
54
|
AML M2
|
13
|
3
|
+
|
+
|
Normal
|
71+
|
||
M
|
54
|
AML M2
|
?
|
1
|
+
|
?
|
G-CSF
|
+8
|
?
|
|
M
|
83
|
AML
|
1
|
1
|
+
|
+
|
G-CSF
|
ND
|
4
|
|
M
|
64
|
AML M5b
|
1
|
NR
|
+
|
+
|
hydroxyurea 5.5 g
|
ND
|
14+
|
|
F
|
62
|
AML
|
?
|
4
|
+
|
?
|
?
|
40
|
||
F
|
60
|
sAML M1
|
2
|
2
|
+ (invasive pulmonary hyalohyphomycosis highly suggestive
of aspergillosis)
|
+
|
G-CSF
|
Normal
|
26+. 2 months after the diagnosis of leukaemia, she achieved
a spontaneous remission lasting 3 months, although neither cytostatic drugs
nor corticoids were administered because of a septic condition. At the
time of remission, a chronic HCV infection and a polyclonal hypergammaglobulinaemia
were present, and the patient received G-CSF factor once
|
|
M
|
31
|
AML M5a
|
1
|
2
|
+
|
|
biphenotypic
|
Normal
|
4+
|
|
? | ? | ? | ? | ? | interstitial pneumonia caused by Pneumocystis carinii | ? | ? | ? | 6 | Fassas et al (1991) |
? | ? | ? | ? | ? | ? | ? | ? | ? | ? | Jimenez et al (1993) |
AML M2 | severe pneumonia. High-dose methylprednisolone was administered, and the leukemic cells disappeared without chemotherapy, although dysplastic hematopoietic cells were observed transiently after the first therapy. After the disappearance of leukemic cells, FISH for AML1 splitting was negative, and RT- PCR results for quantitative chimeric AML1/ MTG8 mRNA were less than the detectable level, however, RT-PCR results for AML1/MTG8 mRNA remained positive. These findings suggest that the patient acquired morphological, cytogenetic, and possibly molecular genetic remission by the synergistic effects of severe infection and high-dose methylprednisoloneref. | t(8;21) (q22:q22). The patient tested positive by FISH for AML1 splitting and positive by RT-PCR for chimeric AML1/MTG8 mRNA, which indicated splitting of the MTG8 gene on chromosome 8 (q22) and the AMLI gene on chromosome 22 (q22) | Shimohakamada et al, 2001 | |||||||
2 cases | ref |
|
|
for |
|